Herman Steen
Directeur Général chez BiOrion Technologies BV
Profil
Herman Steen is the founder of Pharmascope BV, founded in 1998.
He is also the founder of BiOrion Technologies BV, founded in 2003, where he holds the title of Chief Executive Officer starting in 2013.
Additionally, he is the founder of Nyken BV, founded in 2009.
Dr. Steen's former job was as a Clinical Research Associate at Takeda A.
He obtained a graduate degree from the University of Groningen and a doctorate degree from the same university in 1992.
Postes actifs de Herman Steen
| Sociétés | Poste | Début |
|---|---|---|
BiOrion Technologies BV
 BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Directeur Général | 01/01/2003 |
Anciens postes connus de Herman Steen
| Sociétés | Poste | Fin |
|---|---|---|
Nyken BV
 Nyken BV Pharmaceuticals: GenericHealth Technology Nyken BV develops heat-shock-protein drugs for treatment of chronic diseases. Its products include NYK-1001, a drug that is used for the treatment of gastric discomfort and gastric bleeding in China, Japan, and internationally, NYK-1005, a chemical derivative that is used for atrial myocyte screening and drug identifying discovery system and NYK-1007, an early drug candidate used in heat shock proteins. The company was founded by Herman Steen in 2009 and is headquartered in Groningen, the Netherlands. | Directeur Général | - |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Corporate Officer/Principal | - |
| Pharmascope BV | Fondateur | - |
Formation de Herman Steen
| University of Groningen | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |
BiOrion Technologies BV
BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Health Technology |
| Pharmascope BV | |
Nyken BV
Nyken BV Pharmaceuticals: GenericHealth Technology Nyken BV develops heat-shock-protein drugs for treatment of chronic diseases. Its products include NYK-1001, a drug that is used for the treatment of gastric discomfort and gastric bleeding in China, Japan, and internationally, NYK-1005, a chemical derivative that is used for atrial myocyte screening and drug identifying discovery system and NYK-1007, an early drug candidate used in heat shock proteins. The company was founded by Herman Steen in 2009 and is headquartered in Groningen, the Netherlands. | Health Technology |